ArticleAnnals of translational medicine2020

HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.

Xinghui Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.